FY2025 EPS Estimates for VNDA Decreased by Cantor Fitzgerald

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Vanda Pharmaceuticals in a report released on Thursday, May 8th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post earnings per share of ($1.55) for the year, down from their prior estimate of ($1.26). Cantor Fitzgerald currently has a "Overweight" rating and a $13.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($1.12) per share.

A number of other research firms have also recently commented on VNDA. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a "hold" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Vanda Pharmaceuticals Stock Down 1.5%

Shares of VNDA stock traded down $0.06 on Monday, reaching $3.92. The company had a trading volume of 784,178 shares, compared to its average volume of 726,367. The stock has a market capitalization of $231.02 million, a PE ratio of -12.25 and a beta of 0.69. Vanda Pharmaceuticals has a one year low of $3.85 and a one year high of $6.75. The business's 50-day moving average is $4.48 and its 200 day moving average is $4.64.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The company had revenue of $50.04 million for the quarter, compared to analyst estimates of $45.13 million.

Insider Buying and Selling at Vanda Pharmaceuticals

In related news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average cost of $5.02 per share, with a total value of $50,200.00. Following the transaction, the chief executive officer now directly owns 2,285,731 shares in the company, valued at approximately $11,474,369.62. This trade represents a 0.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders bought 32,000 shares of company stock worth $151,180. 10.00% of the stock is currently owned by insiders.

Institutional Trading of Vanda Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in Vanda Pharmaceuticals in the fourth quarter valued at approximately $551,000. Barclays PLC raised its stake in Vanda Pharmaceuticals by 128.2% during the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company's stock worth $722,000 after buying an additional 86,677 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Vanda Pharmaceuticals by 16.1% during the third quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company's stock worth $754,000 after buying an additional 22,249 shares during the last quarter. SG Americas Securities LLC raised its stake in Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock worth $124,000 after buying an additional 5,459 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Vanda Pharmaceuticals by 10.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company's stock valued at $11,920,000 after purchasing an additional 227,428 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.